RELEASE: RELEASE:Cambrex completes $38 million capacity expansion in High Point, North Carolina


RELEASE: RELEASE:Cambrex completes $38 million capacity expansion in High Point, North Carolina

EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, Carolina from North. This expansion doubles the facility's manufacturing capacity, with new state-of-the-art chemical and analytical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation with three work centers and 2,000-liter reactors.

“When we started this project in 2021, our vision extended far beyond capacity,” explained Tom Loewald, CEO of Cambrex. "We designed a facility that can continue to meet customer needs as the industry evolves, with state-of-the-art laboratory technology and equipment, energy-efficient infrastructure, and manufacturing scale from clinical to commercial."

High Point's capabilities complement those of previously acquired Snapdragon Chemistry, which specializes in R&D for API batch and continuous flow process development. The combination of Snapdragon Chemistry and expansion at High Point allows customers to use one supplier to expand flow chemistry from research and development to commercialization.

In addition to the new infrastructure, more than 70 new jobs have been created as Cambrex continues to recruit expert pharmaceutical research and development scientists and staff for the region. Dan Bowles, vice president and general manager of Cambrex High Point added: "We are very excited about this expansion in North Carolina, which would not have been possible without the support of the state's economic development and leadership programs, and its focus on fostering skilled and diverse workforce in the region.

Cambrex continues to expand its capabilities across its North American and European network to meet growing demand for outsourced manufacturing and product development services.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization (CDMO) providing drug substances, drug products and analytical services across the entire drug life cycle. With over 40 years of experience and a growing team of over 2,400 experts serving global customers in North America and Europe, Cambrex is a trusted partner in the generic and branded markets for the development and manufacturing of APIs and forms. finished pharmaceuticals.

Cambrex offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid state science, materials characterization, stability storage and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids and liquids, and has the expertise to manufacture special dosage forms, such as modified-release tablets, fixed-dose combination, pediatric, bi-layer and stick packs, topicals, controlled substances, sterile and non-sterile ointments.


View original content: